Articles Posted in Actos

A personal injury is any kind of accident where you are injured. If you have an accident and feel another party is at fault, you may decide to file what is called a personal injury claim in order to be compensated for damages that may occur from medical or emotional costs associated with the accident.

There are many types of personal injury claims, and while you can file a personal injury claim for just about anything, the most common types of claims are those that involve car accidents, work related injuries, slip and fall accidents, accidents in your home and holiday accidents. Others include product liability claims such as when you are injured from a defective product that you have purchased.

When you file a personal injury claim, you are asked to describe the accident, and provide a dollar amount that you think is suitable compensation. This can include medical and dental bills, money lost due to time missed from not being able to work, or even emotional damage if you can prove your accident caused you emotional or psychological stress.

Attorneys across the U.S. are starting to advertise for and are being contacted by people who took the diabetes drug Actos® and now have bladder cancer.

While France has pulled Actos® off of the market and Germany has recommended to physicians that no new patients begin the drug, in the U.S., Actos® is still being sold with only added warnings to the patient information labels. Physicians have also been give the warning that they should not prescribe Actos® to patients who have bladder cancer or who have had bladder cancer.

Actos® came to the market 10 years ago and it seemed like a perfect Type II diabetes drug because it helped control blood sugar and only had to be taken once a day. For many patients, it meant they would not have to inject insulin.

The problem with Actos® is no one really understood the effects it would have on the body when taken for 5 or 10 years.

The FDA has just released their analysis of five years of data of a 10-year Actos® safety study that began in 2002. The conclusion is that, while the overall number of bladder cancer cases are small, it appears that there are an extra 28 cases a year for every 100,000 people who have taken Actos®. The conclusion is that the risk of risk of bladder cancer was 40% higher for those patients who have taken Actos® for a year or more.

In recent months, personal injury attorneys across the U.S. have been contacted by patients with bladder cancer. Many bladder cancer patients have had to undergo several surgeries and chemotherapy.

The personal injury lawyers at The Farber Law Group feels that Takeda Pharmaceuticals either knew or should have known about the serious risk of bladder cancer. We will work hard to investigate Takeda’s actions and we will do all that we can to help bladder cancer patients who took Actos®.

Related Posts:

FDA announces changes to Actos® diabetes medication labeling

What is the link between bladder cancer and Actos?

French news announces suspension of diabetes drug, Actos Competact
Continue reading

The U.S. Food and Drug Administration issued a notice to the public that they have approved updating drug labels of medications including pioglitazone, including Actos®. The added information states that, in patients using pioglitazone for more than one year, there can be an increased risk of bladder cancer.

The new wording for the label can be found in the Warnings and Precautions section of medicines containing pioglitazone. The patient Medication Guide will also be revised to indicate the bladder cancer association.

The FDA made this action after review a five-year interim analysis of a ten-year epidemiological study which found an increased risk of bladder cancer in patients who had taken Actos® the longest and those who had taken it at higher dosages.

It is interesting to note that the FDA did not suspend the sale of Actos® in this country though France has suspended the use of pioglitazone and Germany has recommended that physicians do not prescribe any new patients with the medication.

The FDA recommends:

  • Patients with bladder cancer should not take Actos®
  • Patients with a history of bladder cancer previously should decide whether the benefits of the drug outweigh the risk.

This information is provided by Washington Injury Attorney blog, a service of The Farber Law Group. We represent people who have been injured due to faulty medical devices and dangerous drugs, including Actos.

Related Posts:

What is the link between bladder cancer and Actos?

French news announces suspension of diabetes drug, Actos Competact

Diabetes drug, Actos, recalled in the French market
Continue reading

Recently the U.S. Food and Drug Administration (FDA) issued warnings that Actos (pioglitazone), a drug to treat Type II Diabetes, may be linked to bladder cancer. The risk is even higher for those patients who take the medication at a higher dosage over an extended period of time according to The Wall Street Journal. Actos is one of several drugs that have contains pioglitazone.

Pioglitazone has been pulled from drug store shelves in France and Germany has recommended not prescribing medication containing pioglitazone to new patients after an epidemiological study by the Caisse National d’Assurance Maladie but it remains on drug store shelves here in the United States.

Takeda Pharmaceuticals, the manufacturer of Actos, has agreed to sponsor a study which looks at link between Actos and bladder cancer.

The FDA’s mid-review of a ten-year epidemiological study of 193,000 patients over the age of 40 with type II diabetes found that the patients who took Actos for more than 12 months had a 40 percent higher risk of developing bladder cancer.

Signs and symptoms of bladder cancer include blood in the urine which may or may not be visible to the eye or detected by microscopic investigation. Other symptoms include painful urination or urgency in urination.

The Farber Law Group, a personal injury law firm in Western Washington, is currently representing people who have bladder cancer and have taken Actos. Fill out our Contact Form if you would like more information.

Related Posts:

French news announces suspension of diabetes drug, Actos Competact

Diabetes drug, Actos, recalled in the French market
Continue reading

The Director General of the Agency of Medicines in France (Afssaps) announced that the diabetes drug Actos Competact, sold as Actos (pioglitazone) in the United States, has been suspended for sale in France because it is responsible for a significant increase in bladder cancer in men according to the French newspaper Le Monde.

Afssaps held a vote and members of the commission voted 25 aye and one abstaining to suspend the sale of the drug after a study by the National Health Insurance (CNAM) found

“a statistically significant association” between exposure to pioglitazone, an antidiabetic medication currently on the hot seat, and the incidence of bladder cancer.”

According to LeMonde, the study shows that the risk of bladder cancer increased by 22% when using Actos. The study showed that the risk increases up to 75% when patients were treated with a high dose. The study followed 1.5 million diabetics, 155,000 who had taken pioglitazone.

Actos was first sold in Europe in 200 and approximately 230,000 patients were treated with the drug in France. The Afssaps warns, “Doctors should no longer prescribe the medicines containing pioglitazone.”

This information is provided by Washington Injury Attorney blog, a service of The Farber Law Group. We are a personal injury law firm and we represent people who are injured due to dangerous drugs, including Actos.

Related Posts:

Diabetes drug, Actos, recalled in the French market

FDA warns that Actos® increases the chance of bladder cancer in patients who have taken the medication for more than one year
Continue reading

Takeda Phamaceutical Co., along with its French subsidiary, Laboratories Takeda, has agreed to withdraw Actos® (pioglitazone) and Competact (pioglitazone and metformin) because of concerns about an increased risk of bladder cancer with the drug.

The two medications are used to treat type II mellitus diabetes which is a form of non-insulin-dependent diabetes. In the U.S., the drug is sold under the name Actos®. Beginning in June of this year, the U.S. Food and Drug Administration added extra warning labels to products containing pioglitazone.
seattle actos bladder cancer lawyer
It appears that France is jumping ahead of the United States by making changes to their drug regulations including ensuring that medications sold in France are safe and also improving patient education and information regarding the risks of medication.

The decision to remove Actos® from the French market came after a study in May by Italian researchers who found a connection between Actos® and bladder cancer.

Some bladder cancer patients in the United States may file lawsuits against Takeda Pharmaceutical for failing to adequately test the drug or warn patients about a bladder cancer risk.

This information is provided by Washington Injury Attorney blog, a service of The Farber Law Group. We are a personal injury law firm with more than 30 years experience representing people who have become ill due to dangerous drugs, including Actos® and drugs containing Pioglitazone.
Continue reading